Decheng Capital is a global life sciences venture capital firm founded in 2012, headquartered in Menlo Park, CA with offices in Shanghai and New York. The firm provides capital and strategic support to early-stage life science companies with revolutionary technologies and growth-stage healthcare companies, managing over $2.5 billion in AUM.
33% of their portfolio is in Biotech & Life Sciences. Deal activity increased 200% year-over-year (6 deals in the last 12 months). Average disclosed round size is $88.4M (across 59 rounds with reported amounts).
Portfolio
49
Fund Size
$700M
Top Stage
Series A
Last 12 Mo
6
Team
Peter Colabuono
Managing Director
Victor Tong, Jr.
Managing Director
Wei Xu
Partner
Aaron Li, MBA
Principal
Min Cui
Founder and Managing Director
Min Cui
Founder and Managing Director
Peter Colabuono
Managing Director
Victor Tong
Managing Director
Victor Tong
Managing Director
Dan Zabrowski
Venture Partner
Qiang Xu
Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Phrontline Biopharma | Series A | — | Sep 2026 |
| VVivacta Biotechnology | Series A | $50M | Apr 2026 |
 Vivacta | Series A | $50M | Apr 2026 |
| SSyneron Bio | Series B | $150M | Mar 2026 |
 Serapha Bio | Series A | $138M | Jan 2026 |
| Phrontline Biopharma | Series C | — | Nov 2025 |
 Excellergy Inc. | Series A | $70M | Oct 2025 |
 Kind Pharmaceuticals | Series C | — | Jan 2025 |
| OOttimo | Series A | $140M | Dec 2024 |
 Ottimo Pharma | Series A | $140M | Dec 2024 |
 Aardvark | Series C | $85M | May 2024 |
 Aardvark Therapeutics | Series C | $85M | May 2024 |
 Nalu | Series E | $65M | Mar 2024 |
 Firefly Bio | Series A | $94M | Feb 2024 |
| Firefly Bio | Series A | $94M | Jan 2024 |
| OOttimo | Series A | $140M | Jan 2024 |
| Nalu | Series E | $85M | Jan 2024 |
 Adela | Series B | $48M | Sep 2023 |
 Grit Bio | Series B | $60M | Sep 2023 |
| UUpstream Bio, Inc. | Series B | $200M | Jun 2023 |
| VVintaBio | Series C | $64M | Apr 2023 |
| Adela | Series B | $48M | Jan 2023 |
| AAcelyrin, Inc | Series C | $300M | Sep 2022 |
 Mirvie | Series B | — | May 2022 |
| IImmPACT Bio USA | Series B | $111M | Jan 2022 |
Top Co-Investors
Last updated: 20 October 2026